Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 20,994 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Completed Phase 2 Interventional Results available

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT02086552
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Sonidegib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1Phase 2 Interventional

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

NCT01183949
View directory record Official record
Conditions
Multiple Myeloma
Interventions
AT7519M, Bortezomib
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Dapivirine Vaginal Ring (VR) in Adolescents

NCT02028338
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
placebo ring, dapivirine ring
Combination Product
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
15 Years to 17 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 2Phase 3 Interventional

Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes

NCT00322478
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Automated informatics driven education and social networking, Blood Glucose Notifications to Remote Caregivers, Frequency of Pattern Management
Behavioral
Lead sponsor
Diabetech
Industry
Eligibility
Not listed
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 22, 2026, 2:18 AM EDT
Not listed No phase listed Observational

Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids

NCT05246085
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cortisol level
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 2:18 AM EDT
Completed No phase listed Observational

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

NCT01946217
View directory record Official record
Conditions
HIV Infection, Malignant Neoplasm, Precancerous Condition
Interventions
questionnaire administration
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 22, 2026, 2:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safer Conception Intervention for HIV-1 Serodiscordant Couples

NCT03030768
View directory record Official record
Conditions
HIV Seropositivity, Pregnancy, High-Risk
Interventions
PrEP, Counseling on timed condomless sex, ART and PrEP adherence
Drug · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

EXTEND (Eltrombopag Extended Dosing Study)

NCT00351468
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag olamine (SB-497115-GR)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 22, 2026, 2:18 AM EDT
Completed No phase listed Observational Results available

Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients

NCT00262314
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 22, 2026, 2:18 AM EDT
Recruiting Not applicable Interventional

Sleep Coach for Adolescents With Type 1 Diabetes

NCT06516614
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sleep Coach, Diabetes Education
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
11 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 2:18 AM EDT
Terminated Phase 1 Interventional

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma
Interventions
CART-TnMUC1, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed No phase listed Observational

Consistency of Traditional Chinese Medicine Diagnoses and Herbal Prescriptions for Rheumatoid Arthritis

NCT00071149
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

NCT00003838
View directory record Official record
Conditions
Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Interventions
T-cell replete PBPC allograft, Methotrexate, Cyclosporine, G-CSF
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Not applicable Interventional

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

NCT00186355
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
high dose chemo then auto hematopoietic cell transplant
Procedure
Lead sponsor
Stanford University
Other
Eligibility
4 Weeks to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Parent Understanding of Instructions About Asthma Care

NCT01405625
View directory record Official record
Conditions
Asthma
Interventions
Pictogram-based asthma action plan, AAAAI standard of care written action plan
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 22, 2026, 2:18 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

NCT06561425
View directory record Official record
Conditions
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell
Interventions
GLPG5101
Genetic
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 2:18 AM EDT
Terminated No phase listed Observational

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

NCT00900068
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
immunoenzyme technique, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 3 Interventional

The Treatment of Tuberculosis in HIV-Infected Patients

NCT00001033
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 2:18 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

NCT01574248
View directory record Official record
Conditions
ACE Inhibitor-associated Angioedema
Interventions
icatibant, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Diego, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 22, 2026, 2:18 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 2:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
povorcitinib, placebo, ICS-LABA
Drug · Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Bakersfield, California • Upland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose

NCT00882115
View directory record Official record
Conditions
Allergic Airway Disease
Interventions
Broccoli sprout extract (BSE)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

Management of Pruritus With Xyzal in Atopic Dermatitis

NCT00884325
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
Levocetirizine dihydrochloride (Xyzal), placebo
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

NCT00006097
View directory record Official record
Conditions
Leukemia
Interventions
CC-1088
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Oct 22, 2026, 2:18 AM EDT